REFERENCES
1. Ridgway D. The first 1000 dendritic cell vaccines. Cancer Invest. 2003;21(6):873–86.
2. Cranmer LD, Trevor KT, Hersh EM. Clinical applications of dendritic cell vaccination in the treatment of cancer. Cancer
Immunol Immunother. 2004;53(4):275–306.
3. Banchereau J, Briere F, Caux C, Davoust J, Lebecque S, Liu YJ, et al. Immunobiology of dendritic cells. Annu Rev Immunol.
2000;18:767–811.
4. Steinman RM. The dendritic cell system and its role in immunogenicity. Annu Rev Immunol. 1991;9:271–96.
5. Sabado RL, Babcock E, Kavanagh DG, Tjomsland V, Walker BD, et al. Pathways utilized by dendritic cells for binding, uptake,
processing and presentation of antigens delivered from HIV-1. Eur J Immunol. 2007;Epub ahead of print, May 29.
6. Ferris RL, Whiteside TL, Ferrone S. Immune escape associated with functional defects in antigen processing machinery in
head and neck cancer. Clin Cancer Res. 2007;12(13):3890–3895.
7. Sallusto F, Lanzavecchia A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained
by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and down-regulated by tumor necrosis factor-alpha.
J Exp Med. 1994;179(4):1109–18.
8. Wesa A, Kalinski P, Kirkwood JM, Tatsumi T, Storkus, WJ. Polarized type-1 dendritic cells (DC1) producing high levels
of IL-12 family members rescue patient TH1-type antimelanoma CD4+ T cell responses in vitro. J Immunother. 1997;30(1):75–82.
9. Dudziak D, Kamphorst AO, Heidkamp, GF, et al. Differential antigen processing by dendritic cell subsets in vivo. Science.
2007;315(5808):107–111.
10. Liu YJ. Dendritic cell subsets and lineages, and their functions in innate and adaptive immunity. Cell. 2001;106(3):259–62.
11. Moser M, Murphy KM. Dendritic cell regulation of TH1-TH2 development. Nat Immunol. 2000;1(3):199–205.
12. Banchereau J, Schuler-Thurner B, Palucka AK, Schuler G. Dendritic cells as vectors for therapy. Cell. 2001;106(3):271–4.
13. Palucka AK, Ueno H, Connolly J, Kerneis-Norvell F, et al. Dendritic cells loaded with killed allogeneic melanoma cells
can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity. J Immunother. (1997) 2006;29(5):545–57.
14. Gilboa E. DC-based cancer vaccines. J Clin Invest. 2007;117(5):1195–1203.
15. Connolly NC, Whiteside TL, Wilson C, et al. Therapeutic immunization with HIV-1 peptide-loaded dendritic cells is safe
and immunogenic in HIV-1-infected individuals. Clin Vaccine Immunol. 2007; In press.
16. Lu W, Arraes LC, Ferreira WT, Andrieu JM. Therapeutic dendritic-cell vaccine for chronic HIV-1 infection. Nat Med. 2004;10:1359–1365.
17. Lo J, Clare-Salzler MJ. Dendritic cell subsets and type I diabetes: focus upon DC-based therapy. Autoimmune Rev. 2006;5(6):419–23.
18. Young JW, Merad M, Hart DN. Dendritic cells in transplantation and immune-based therapies. Biol Blood Marrow Transplant.
2007;13(1):23–32.
19. Morse MA, Lyerly HK, Li Y. The role of IL-13 in the generation of dendritic cells in vitro. J Immunother. 1999;22(6):506–13.
20. Curti A, Fogli M, Ratta M, Biasco G, Tura S, Lemoli RM. Dendritic cell differentiation from hematopoietic CD34+ progenitor
cells. J Biol Regul Homeost Agents. 2001;15(1):49–52.
|
